Search Results - "Pagel, M"

Current and future treatment strategies in chronic lymphocytic leukemia by Patel, Krish, Pagel, John M

“…Treatment decisions for patients with chronic lymphocytic leukemia (CLL) are dependent on symptoms and classification into high-, medium-, or low-risk…”
Get full text

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia by Byrd, John C, Harrington, Bonnie, O’Brien, Susan, Jones, Jeffrey A, Schuh, Anna, Devereux, Steve, Chaves, Jorge, Wierda, William G, Awan, Farrukh T, Brown, Jennifer R, Hillmen, Peter, Stephens, Deborah M, Ghia, Paolo, Barrientos, Jacqueline C, Pagel, John M, Woyach, Jennifer, Johnson, Dave, Huang, Jane, Wang, Xiaolin, Kaptein, Allard, Lannutti, Brian J, Covey, Todd, Fardis, Maria, McGreivy, Jesse, Hamdy, Ahmed, Rothbaum, Wayne, Izumi, Raquel, Diacovo, Thomas G, Johnson, Amy J, Furman, Richard R

“…Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had…”
Get full text

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma by Wang, Michael, Munoz, Javier, Goy, Andre, Locke, Frederick L, Jacobson, Caron A, Hill, Brian T, Timmerman, John M, Holmes, Houston, Jaglowski, Samantha, Flinn, Ian W, McSweeney, Peter A, Miklos, David B, Pagel, John M, Kersten, Marie-Jose, Milpied, Noel, Fung, Henry, Topp, Max S, Houot, Roch, Beitinjaneh, Amer, Peng, Weimin, Zheng, Lianqing, Rossi, John M, Jain, Rajul K, Rao, Arati V, Reagan, Patrick M

“…Patients with mantle-cell lymphoma who have a relapse after chemotherapy and anti-CD20 and BTK inhibitor therapy have a poor prognosis. An injection of…”
Get full text

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab by Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.

“…Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase…”
Get full text

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation by Walter, R B, Gyurkocza, B, Storer, B E, Godwin, C D, Pagel, J M, Buckley, S A, Sorror, M L, Wood, B L, Storb, R, Appelbaum, F R, Sandmaier, B M

“…Minimal residual disease (MRD) is associated with adverse outcome in acute myeloid leukemia (AML) after myeloablative (MA) hematopoietic cell transplantation…”
Get full text

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission by Walter, Roland B., Buckley, Sarah A., Pagel, John M., Wood, Brent L., Storer, Barry E., Sandmaier, Brenda M., Fang, Min, Gyurkocza, Boglarka, Delaney, Colleen, Radich, Jerald P., Estey, Elihu H., Appelbaum, Frederick R.

“…Minimal residual disease (MRD) before myeloablative hematopoietic cell transplantation (HCT) is associated with adverse outcome in acute myeloid leukemia (AML)…”
Get full text

Phylogenetic Analysis and Comparative Data: A Test and Review of Evidence by Freckleton, R. P., Harvey, P. H., Pagel, M.

“…The question is often raised whether it is statistically necessary to control for phylogenetic associations in comparative studies. To investigate this…”
Get full text

Magnetite-Loaded Polymeric Micelles as Ultrasensitive Magnetic-Resonance Probes by Ai, H., Flask, C., Weinberg, B., Shuai, X.-T., Pagel, M. D., Farrell, D., Duerk, J., Gao, J.

“…Increased contrast in magnetic resonance imaging (MRI) is accomplished using polymeric micelles loaded with superparamagnetic iron oxide (SPIO) nanoparticles…”
Get full text

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia by WALTER, Roland B, GOOLEY, Ted A, GOPAL, Ajay K, APPELBAUM, Frederick R, PAGEL, John M, WOOD, Brent L, MILANO, Filippo, MIN FANG, SORROR, Mohamed L, ESTEY, Elihu H, SALTER, Alexander I, LANSVERK, Emily, CHIEN, Jason W

“…Allogeneic hematopoietic cell transplantation (HCT) benefits many patients with acute myeloid leukemia (AML) in first remission. Hitherto, little attention has…”
Get full text

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients by Brown, Jennifer R, Byrd, John C, Ghia, Paolo, Sharman, Jeff P, Hillmen, Peter, Stephens, Deborah M, Sun, Clare, Jurczak, Wojciech, Pagel, John M, Ferrajoli, Alessandra, Patel, Priti, Tao, Lin, Kuptsova-Clarkson, Nataliya, Moslehi, Javid, Furman, Richard R

“…Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic…”
Get full text

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison by Al-Sawaf, Othman, Jen, Min-Hua, Hess, Lisa M, Zhang, Jiewen, Goebel, Benjamin, Pagel, John M, Abhyankar, Sarang, Davids, Matthew S, Eyre, Toby A

“…Venetoclax is a standard treatment for patients with chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy,…”
Get full text

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice by Roeker, Lindsey E, Fox, Christopher P, Eyre, Toby A, Brander, Danielle M, Allan, John N, Schuster, Stephen J, Nabhan, Chadi, Hill, Brian T, Shah, Nirav N, Lansigan, Frederick, Yazdy, Maryam, Cheson, Bruce D, Lamanna, Nicole, Singavi, Arun K, Coombs, Catherine C, Barr, Paul M, Skarbnik, Alan P, Shadman, Mazyar, Ujjani, Chaitra S, Tuncer, Hande H, Winter, Allison M, Rhodes, Joanna, Dorsey, Colleen, Morse, Hannah, Kabel, Charlene, Pagel, John M, Williams, Annalynn M, Jacobs, Ryan, Goy, Andre, Muralikrishnan, Sivraj, Pearson, Laurie, Sitlinger, Andrea, Bailey, Neil, Schuh, Anna, Kirkwood, Amy A, Mato, Anthony R

“…Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using…”
Get full text

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS by Deeg, H. Joachim, Scott, Bart L., Fang, Min, Shulman, Howard M., Gyurkocza, Boglarka, Myerson, David, Pagel, John M., Platzbecker, Uwe, Ramakrishnan, Aravind, Radich, Jerald P., Sandmaier, Brenda M., Sorror, Mohamed, Stirewalt, Derek L., Wilson, Wendy A., Storb, Rainer, Appelbaum, Frederick R., Gooley, Ted

“…Clonal cytogenetic abnormalities are a major risk factor for relapse after hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS). We…”
Get full text

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies by Allan, John N, Pinilla-Ibarz, Javier, Gladstone, Douglas E, Patel, Krish, Sharman, Jeff P, Wierda, William G, Choi, Michael Y, O'Brien, Susan M, Shadman, Mazyar, Davids, Matthew S, Pagel, John M, Yimer, Habte A, Ward, Renee, Acton, Gary, Taverna, Pietro, Combs, Daniel L, Fox, Judith A, Furman, Richard R, Brown, Jennifer R

Get full text

Detecting Correlated Evolution on Phylogenies: A General Method for the Comparative Analysis of Discrete Characters by Pagel, Mark

“…I present a new statistical method for analysing the relationship between two discrete characters that are measured across a group of hierarchically evolved…”
Get full text

Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration by Stephens, Deborah M, Boucher, Ken, Kander, Elizabeth, Parikh, Sameer A, Parry, Erin M, Shadman, Mazyar, Pagel, John M, Cooperrider, Jennifer, Rhodes, Joanna, Mato, Anthony, Winter, Allison, Hill, Brian, Gaballa, Sameh, Danilov, Alexey, Phillips, Tycel, Brander, Danielle M, Smith, Sonali M, Davids, Matthew, Rogers, Kerry, Glenn, Martha J, Byrd, John C

“…Chronic lymphocytic leukemia (CLL) patients who develop Hodgkin lymphoma (HL) have limited survival. No current therapeutic standard of care exists. We…”
Get full text

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia by Vo, Phuong, Gooley, Ted A, Rajendran, Joseph G, Fisher, Darrell R, Orozco, Johnnie J, Green, Damian J, Gopal, Ajay K, Haaf, Robyn, Nartea, Margaret, Storb, Rainer, Appelbaum, Frederick R, Press, Oliver W, Pagel, John M, Sandmaier, Brenda M

“…Outcomes of patients with persistent high-risk leukemia or myelodysplasia prior to allogeneic hematopoietic cell transplantation are dismal. We therefore…”
Get full text

A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders by TIMMERMAN, John M, BYRD, John C, ANDORSKY, David J, YAMADA, Reiko E, KRAMER, Janet, MUTHUSAMY, Natarajan, HUNDER, Naomi, PAGEL, John M

“…We conducted a phase I study to determine the safety, maximum-tolerated dose (MTD), and efficacy of weekly bolus recombinant human interleukin-21 (rIL-21) plus…”
Get full text

Use of the IL‐6R antagonist tocilizumab in hospitalized COVID‐19 patients by Patel, K., Gooley, T. A., Bailey, N., Bailey, M., Hegerova, L., Batchelder, A., Holdread, H., Dunleavy, V., Downey, T., Frisvold, J., Megrath, S., Pagarigan, K., Szeto, J., Rueda, J., Islam, A., Maree, C., Nyatsatsang, S., Bork, S. E., Lipke, A., O’Mahony, D. S., Wagner, T., Pulido, J., Mignone, J., Youssef, S., Hartman, M., Goldman, J. D., Pagel, J. M.

Get full text

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study by Mato, Anthony R, Shah, Nirav N, Jurczak, Wojciech, Cheah, Chan Y, Pagel, John M, Woyach, Jennifer A, Fakhri, Bita, Eyre, Toby A, Lamanna, Nicole, Patel, Manish R, Alencar, Alvaro, Lech-Maranda, Ewa, Wierda, William G, Coombs, Catherine C, Gerson, James N, Ghia, Paolo, Le Gouill, Steven, Lewis, David John, Sundaram, Suchitra, Cohen, Jonathon B, Flinn, Ian W, Tam, Constantine S, Barve, Minal A, Kuss, Bryone, Taylor, Justin, Abdel-Wahab, Omar, Schuster, Stephen J, Palomba, M Lia, Lewis, Katharine L, Roeker, Lindsey E, Davids, Matthew S, Tan, Xuan Ni, Fenske, Timothy S, Wallin, Johan, Tsai, Donald E, Ku, Nora C, Zhu, Edward, Chen, Jessica, Yin, Ming, Nair, Binoj, Ebata, Kevin, Marella, Narasimha, Brown, Jennifer R, Wang, Michael

“…Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and…”
Get full text